Adriano José Maia Chaves Filho

Adriano José Maia Chaves Filho

Auto-generated profile, based on publicly available information

Adriano José Maia Chaves Filho

Universidade Federal do Ceará, Brasil

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Journal of Affective Disorders
Verified
Journal Article
Closed access
DMDanielle Macedo
Danielle Macedo
AFAdriano José Maia Chaves Filho
Adriano José Maia Chaves Filho
CSCaren Nádia Soares de Sousa
Caren Nádia Soares de Sousa
JQJoão Quevedo
João Quevedo
BTBarichello Tatiana
Barichello Tatiana
DLDavid Freitas de Lucena
David Freitas de Lucena

1 January 2018 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
AFAdriano José Maia Chaves Filho
Adriano José Maia Chaves Filho
CLCamila Nayane Carvalho Lima
Camila Nayane Carvalho Lima
SVSilvania Vasconcelos
Silvania Vasconcelos
DLDavid Freitas de Lucena
David Freitas de Lucena
MMMichael Maes
Michael Maes
DMDanielle Macedo
Danielle Macedo

23 May 2017 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
CCCharllyany Sabino Custódio
Charllyany Sabino Custódio
BMBruna Stefânia Ferreira Mello
Bruna Stefânia Ferreira Mello
AFAdriano José Maia Chaves Filho
Adriano José Maia Chaves Filho
CLCamila Nayane De Carvalho Lima
Camila Nayane De Carvalho Lima
RCRafaela Carneiro Cordeiro
Rafaela Carneiro Cordeiro
DMDanielle Macedo
Danielle Macedo

1 December 2016 in Phytomedicine
Verified
Journal Article
Closed access
TSTiago Lima Sampaio
Tiago Lima Sampaio
Ramon Róseo Paula Pessoa Bezerra de MenezesRamon Róseo Paula Pessoa Bezerra de Menezes
Ramon Róseo Paula Pessoa Bezerra de Menezes
MCMarcus Felipe Bezerra da Costa
Marcus Felipe Bezerra da Costa
GMGdayllon Cavalcante Meneses
Gdayllon Cavalcante Meneses
MAMauren Cristina Villalta Arrieta
Mauren Cristina Villalta Arrieta
AMAlice Maria Costa Martins
Alice Maria Costa Martins

19 March 2024 in Journal of Neurochemistry
Verified
Journal Article
Open access
ACAdriano Chaves‐Filho
Adriano Chaves‐Filho
CECapri Eyres
Capri Eyres
LBLeonie Blöbaum
Leonie Blöbaum
ALAntonia Landwehr
Antonia Landwehr
MTMarie‐Ève Tremblay
Marie‐Ève Tremblay
Bipolar disorder (BD) is a severe and multifactorial disease, with onset usually in young adulthood, which follows a progressive course throughout life. Replicated epidemiological studies have suggested inflammatory mechanisms and neuroimmune risk factors as primary contributors to the onset and development of BD. While not all patients display overt markers of inflammation, significant evidence suggests that aberrant immune signaling contributes to all stages of the disease and seems to be mood phase dependent, likely explaining the heterogeneity of findings observed in this population. As the brain's immune cells, microglia orchestrate the brain's immune response and play a critical role in maintaining the brain's health across the lifespan. Microglia are also highly sensitive to environmental changes and respond to physiological and pathological events by adapting their functions, structure, and molecular expression. Recently, it has been highlighted that instead of a single population of cells, microglia comprise a heterogeneous community with specialized states adjusted according to the local molecular cues and intercellular interactions. Early evidence has highlighted the contribution of microglia to BD neuropathology, notably for severe outcomes, such as suicidality. However, the roles and diversity of microglial states in this disease are still largely undermined. This review brings an updated overview of current literature on the contribution of neuroimmune risk factors for the onset and progression of BD, the most prominent neuroimmune abnormalities (including biomarker, neuroimaging, ex vivo studies) and the most recent findings of microglial involvement in BD neuropathology. Combining these different shreds of evidence, we aim to propose a unifying hypothesis for BD pathophysiology centered on neuroimmune abnormalities and microglia. Also, we highlight the urgent need to apply novel multi‐system biology approaches to characterize the diversity of microglial states and functions involved in this enigmatic disorder, which can open bright perspectives for novel biomarkers and therapeutic discoveries. image

1 December 2017 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
LSLia Lira Olivier Sanders
Lia Lira Olivier Sanders
CMCarlos Eduardo de Souza Menezes
Carlos Eduardo de Souza Menezes
AFAdriano José Maia Chaves Filho
Adriano José Maia Chaves Filho
GVGlautemberg de Almeida Viana
Glautemberg de Almeida Viana
FFFrancisco Vagnaldo Fechine
Francisco Vagnaldo Fechine
DLDavid Freitas de Lucena
David Freitas de Lucena
Purpose/Background: Accumulating evidence suggests an involvement of oxidative stress in the pathophysiology of schizophrenia. This offers a hypothesis-derived therapeutic approach to hinder oxidative damage and its clinical sequelae. α-Lipoic acid (ALA) is a powerful natural antioxidant indicated to treat diabetic neuropathy. Methods/Procedures: In this pilot investigation, we administered ALA (100 mg/d) for 4 months, as an adjunct to antipsychotic medication, to 10 patients with schizophrenia. Findings/Results: We found robust improvement in measures of psychopathology (63.9% reduction in Brief Psychiatric Rating Scale scores), neurocognitive parameters, extrapyramidal symptoms, and decreased lipid peroxidation. Implications/Conclusions: If larger, double-blind, placebo-controlled studies confirm these preliminary findings, ALA could prove useful as adjunctive therapy for schizophrenia.